Concise Prescribing Info
Treatment & prevention of neutropenia in patients receiving myelosuppressive cancer chemotherapy & to reduce the period of neutropenia in patients undergoing bone marrow transplantation. Mobilize peripheral blood progenitor cells in the management of chronic neutropenia (congenital, cyclic or idiopathic) & persistent neutropenia in patients w/ advanced HIV infection.
Dosage/Direction for Use
Adjunct to antineoplastic therapy 5 mcg/kg starting not <24 hr after the last dose of antineoplastic, by single SC inj daily, continuous IV or SC infusion, or by IV infusion over 15-30 min. Continue treatment until neutrophil count is stabilized w/in the normal range which may take up to ≥14 days. Reduce incidence of neutropenia associated w/ antineoplastic therapy A formulation of filgrastim conjugated w/ monomethoxy polyethylene glycol given SC in a single dose of 6 mg, not <24 hr after the last dose of antineoplastic. Bone marrow transplantation Initially 10 mcg/kg daily by IV infusion over 30 min or 4 hr, or by continuous IV or SC infusion over 24 hr. Mobilisation of peripheral blood progenitor cells 10 mcg/kg as single SC inj daily or by continuous infusion for 4-7 days until leucapheresis. After myelosuppressive chemotherapy 5 mcg/kg by SC inj daily. Patient w/ congenital neutropenia Initially 12 mcg/kg daily. Patient w/ idiopathic or cyclic neutropenia Initially 5 mcg/kg daily. Doses are administered SC in single or divided doses. Patient w/ HIV infection & persistent neutropenia Initially 1 mcg/kg by SC inj daily. Max: 4 mcg/kg daily. Maintenance: 300 mcg daily for 1-7 days a wk.
Hypersensitivity. Childn or adolescents <4 kg.
Special Precautions
Avoid simultaneous use w/ chemotherapy & radiation therapy. Avoid in patients receiving cytotoxic drugs 24 hr before or after chemotherapy. Potential effect on malignant cells. Regularly monitor patients w/ history of gout or malignancies associated w/ increased uric acid levels. Pregnancy & lactation. Neonates & patients w/ autoimmune neutropenia of infancy.
Adverse Reactions
Mild to moderate (occasionally severe) medullary bone pain. Pyrexia, vomiting, diarrhea, asthenia, generalized pain, cough, abdominal pain, anemia, pain in extremity, nausea, anorexia, hypoesthesia, paresthesia, mucosal inflammation & dysuria.
Drug Interactions
Caution w/ drugs that may potentiate release of neutrophils eg, lithium.
MIMS Class
Haematopoietic Agents / Supportive Care Therapy
ATC Classification
L03AA02 - filgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
Religrast soln for inj 300 mcg/0.5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in